Myelodysplastic Syndrome With Autoimmune Disease: Clinical and Molecular Features and Survival Outcomes
Clinical Lymphoma Myeloma and Leukemia · 2026-08 · 26 (8) · e1043-e1052.e2
DOI: 10.1016/j.clml.2026.06.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-08. Verfasst von Yunsuk Choi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Autoimmune Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Asan Medical Center Asan Institute for Life Sciences.
Abstract (Originalsprache)
BACKGROUND The myelodysplastic syndromes (MDS) frequently present with heterogeneous systemic inflammatory and autoimmune disease (AD). However, the pathobiology and prognostic impact of AD in MDS have not been fully elucidated. Therefore, we aimed to investigate cytogenetic and molecular characteristics and prognostic significance of autoimmune disease in MDS. METHODS We retrospectively analyzed 1456 patients diagnosed with MDS at Asan Medical Center, Seoul, Korea, between 1989 and 2021. RESULTS Among all patients, 90 (6.2%) had AD. The most frequent cytogenetic abnormalities in AD+ group were trisomy 8 (22.2%), complex karyotypes (5.6%), and der (1;7) (q10;p10) (4.4%). BCORL1 (9.8% vs. 1.2%, P = .006) was significantly more frequent in AD+ patients. SETD2 (4.9% vs. 0.7%, P = .069) and WT1 mutations (7.3% vs. 1.7%, P = .055) showed a trend toward higher frequency in the AD+ group. The MDS patients with AD+ demonstrated significantly higher overall survival (OS) (58.7% vs. 40.7% at 5 years, P = .011) and leukemia-free survival (LFS) rates (53.9% vs. 34.7%, P = .006) compared to those without AD. In multivariable analyses, AD remained independently associated with improved OS (HR, 0.69; 95% CI, 0.50-0.96; P = .029) and LFS (HR, 0.64; 95% CI, 0.47-0.89; P = .007). Similar findings were observed in sensitivity analyses restricted to patients with definite autoimmune diseases. The favorable prognostic impact of AD was significant, particularly in higher-risk MDS. CONCLUSION In conclusion, AD identifies a distinct subgroup of patients with MDS with favorable clinical outcomes. Trisomy 8 and BCORL1 mutations were enriched in patients with AD. Further studies are warranted to clarify the underlying mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Electronic address: jhlee3@amc.seoul.kr.
Förderung
- Asan Medical Center Asan Institute for Life Sciences
Zitieren
APA
Choi, Y., Choi, E. J., Park, H., Cho, Y. U., Hur, J. Y., Lee, J. H., Jeong, J., Cha, S., Lee, Y. S., Jeon, M., Woo, J. M., Kang, Y. A., Kang, H., & Lee, J. H. (2026). Myelodysplastic Syndrome With Autoimmune Disease: Clinical and Molecular Features and Survival Outcomes. Clinical Lymphoma Myeloma and Leukemia, 26(8), e1043-e1052.e2. https://doi.org/10.1016/j.clml.2026.06.004
Vancouver
Choi Y, Choi EJ, Park H, Cho YU, Hur JY, Lee JH, et al. Myelodysplastic Syndrome With Autoimmune Disease: Clinical and Molecular Features and Survival Outcomes. Clinical Lymphoma Myeloma and Leukemia. 2026;26(8):e1043-e1052.e2. doi:10.1016/j.clml.2026.06.004
BibTeX
@article{Choi2026,
author = {Choi, Yunsuk and Choi, Eun-Ji and Park, Hyunkyung and Cho, Young-Uk and Hur, Joon Young and Lee, Jung-Hee and Jeong, Jisoo and Cha, Seungah and Lee, Young-Shin and Jeon, Mijin and Woo, Ji Min and Kang, Young-Ah and Kang, Hyeran and Lee, Je-Hwan},
title = {Myelodysplastic Syndrome With Autoimmune Disease: Clinical and Molecular Features and Survival Outcomes},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {8},
pages = {e1043--e1052.e2},
doi = {10.1016/j.clml.2026.06.004}
}
EUVIMED